Rosuvastatin: a highly effective new HMG‐CoA reductase inhibitor
AG Olsson, F McTaggart, A Raza - Cardiovascular drug …, 2002 - Wiley Online Library
Rosuvastatin, a new statin, has been shown to possess a number of advantageous
pharmacological properties, including enhanced HMG‐CoA reductase binding …
pharmacological properties, including enhanced HMG‐CoA reductase binding …
Rosuvastatin
CI Carswell, GL Plosker, B Jarvis - Drugs, 2002 - Springer
Abstract▴ Rosuvastatin is a hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase
inhibitor used in the treatment of patients with dyslipidaemia. Rosuvastatin is not extensively …
inhibitor used in the treatment of patients with dyslipidaemia. Rosuvastatin is not extensively …
[PDF][PDF] Kardiologie
Ö Herzfonds - Cardiology, 2006 - academia.edu
Background B-type natriuretic peptide (BNP) has been studied in aortic stenosis (AS), but no
data have been reported for patients with low-flow/low-gradient AS. Therefore, we studied …
data have been reported for patients with low-flow/low-gradient AS. Therefore, we studied …
[引用][C] 73. Europäischer Atherosklerosekongreß in Salzburg, 7.–10. Juli 2002: Rosuvastatin
K Kostner - Journal of Cardiology, 2002